Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055625 | 0.97 | CHRNA7 (0.55) | KCNH2CHRNA7HRH3CHRNA3 | |
| SCHEMBL2055877 | 0.93 | GSK3A (0.48) | KCNH2CHRNA7HRH3CHRNA3GSK3A | |
| SCHEMBL2055654 | 0.91 | GSK3A (0.50) | KCNH2CHRNA7HRH3CHRNA3GSK3A | |
| SCHEMBL2055844 | 0.90 | CHRNA3 (0.51) | KCNH2CHRNA7HRH3CHRNA3GSK3A | |
| SCHEMBL2055597 | 0.88 | KCNH2 (0.58) | KCNH2CHRNA7CHRNA3 | |
| SCHEMBL2055626 | 0.87 | CHRNA3 (0.55) | KCNH2HRH3CHRNA3GSK3AGSK3B | |
| SCHEMBL2055607 | 0.87 | CHRNA3 (0.55) | KCNH2HRH3CHRNA3GSK3AGSK3B | |
| SCHEMBL2055632 | 0.87 | KCNH2 (0.57) | KCNH2CHRNA7CHRNA3 | |
| SCHEMBL2055694 | 0.86 | CHRNA7 (0.59) | KCNH2CHRNA7CHRNA3GSK3AGSK3B | |
| SCHEMBL2055592 | 0.86 | CHRNA7 (0.59) | KCNH2CHRNA7CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163729-B2 | Modulators of α7 nicotinic acetylcholine receptors and therapeutic uses thereof | WYETH (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | KCNH2 1263/4885CHRNA7 1/4885HRH3 493/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | KCNH2 909/4885CHRNA7 1/4885HRH3 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.